RxDoctor Payments Data

Daniel Malach, MD

Ophthalmology · Detroit, MINPI 1487003612

Payments from drug & device makers

$4,463in general payments, 2019–2025

Across 94 payments — averaging $47.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Bausch & Lomb Americas Inc.$625
  • Regeneron Healthcare Solutions, Inc.$380
  • Glaukos Corporation$270
  • Novartis$261
  • Sun Pharmaceutical Industries Inc.$215
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,463100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,463 in reported general payments places this provider in the 80th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$219,633
Medicare patients
621
Services billed
2,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost87$43,857
RestasisCyclosporine42$31,013
Latanoprost351$6,598
Cyclosporine13$5,414
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$4,593
VyzultaLatanoprostene Bunod11$4,433
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat118$4,209
Brimonidine Tartrate68$3,786
SimbrinzaBrinzolamide/Brimonidine Tart12$3,135
Prednisolone Acetate41$1,835
Tobramycin-DexamethasoneTobramycin/Dexamethasone56$1,828
Timolol Maleate71$1,192
Atropine Sulfate36$897
Dorzolamide Hcl39$831
Doxycycline Hyclate12$300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$625$4,43311 claims
AlconSimbrinza$1,582$3,13512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →